1. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.
- Author
-
Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gøtze JP, Johansen JS, and Kastrup J
- Subjects
- Adipokines, Aged, Chitinase-3-Like Protein 1, Cholesterol blood, Female, Humans, Male, Middle Aged, Biomarkers blood, C-Reactive Protein immunology, Coronary Artery Disease blood, Coronary Artery Disease drug therapy, Coronary Artery Disease immunology, Glycoproteins blood, Glycoproteins immunology, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Inflammation blood, Inflammation immunology, Lectins blood, Lectins immunology
- Abstract
Objective: The inflammatory biomarker YKL-40 is elevated and associated with mortality in patients with stable coronary artery disease (CAD). The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD., Design: Serum YKL-40, HsCRP, total cholesterol, HDL-c, LDL-c and triglycerides levels were measured in 404 statin treated and in 404 matched non-statin treated patients with stable CAD., Results: YKL-40 was significantly higher in non-statin treated 110 µg/l (median) compared with 65 µg/l in statin treated (p < 0.001). HsCRP was 3.3 mg/l in non-statin treated compared with 2.1 mg/l in statin treated (p < 0.001). YKL-40 was not related to cholesterol levels for either statin or non-statin treated patients in the univariate analysis. In statin treated patients, HsCRP was related to a high level of total-cholesterol (p = 0.01) and a low level of HDL-c (p < 0.001)., Conclusions: HsCRP, but not YKL-40, is associated with the cholesterol levels in statin treated patients. This indicates that YKL-40 could be a superior prognostic biomarker in patients with stable CAD, since it is independent of changes in cholesterol levels in both statin and non-statin treated patients.
- Published
- 2011
- Full Text
- View/download PDF